Menu Search
Equities

Lytix Biopharma AS

LYTIX:OSL

Lytix Biopharma AS

Actions
  • Price (NOK)7.88
  • Today's Change0.34 / 4.51%
  • Shares traded89.06k
  • 1 Year change+5.24%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in NOKIncome statement in NOKView more

Year on year Lytix Biopharma AS's revenues fell -63.82% from 11.03m to 3.99m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 56.07m to a larger loss of 87.90m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in NOKView more

In 2023, cash reserves at Lytix Biopharma AS fell by 67.19m. However, Cash Flow from Investing totalled 29.73m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 95.97m for operations while cash used for financing totalled 943.00k.
Cash flow per share--
Price/Cash flow per share--
Book value per share1.19
Tangible book value per share1.19
More ▼

Balance sheet in NOKView more

Lytix Biopharma AS has little financial risk as the capital structure does not rely on leverage.
Current ratio4.61
Quick ratio--
Total debt/total equity0.0506
Total debt/total capital0.0482
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.